At a glance
ClinicalIndex Comparison RecordPhase 2Active· 32 enrolled
Drug / intervention
IPI-145 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2 Study of IPI-145 in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia.
In Brief
A Phase 2 clinical trial evaluating IPI-145, Fludarabine, and 2 other interventions for Chronic Lymphocytic Leukemia. Active but no longer recruiting, targeting 32 participants across 2 sites.
Detailed Summary
This research study is evaluating a new drug called IPI-145 in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR), as a possible treatment for chronic lymphocytic leukemia (CLL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia
CountriesUnited States
CollaboratorsSecura Bio, Inc.
Timeline
Phase 2ActiveOverdue
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartJun 2014
Primary CompletionOct 2017
Study CompletionJul 2026
TodayJul 2026
First PostedJun 6, 2014
Enrollment StartJun 27, 2014
Primary CompletionOct 1, 2017
Study CompletionJul 1, 2026
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 12.1 years ago
Interventions
IPI-145drug
oral PI3K delta/gamma inhibitor
Fludarabinedrug
intravenous chemotherapy
Cyclophosphamidedrug
intravenous chemotherapy
Rituximabdrug
intravenous immunotherapy